Herbert Barton Grossman

Herbert Barton Grossman's AcademicInfluence.com Rankings

Philosophy

#8805

World Rank

#12257

Historical Rank

Logic

#5822

World Rank

#7262

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Herbert Barton Grossman's Degrees

Doctorate Medicine Harvard University
PhD Biomedical Sciences Stanford University

Why Is Herbert Barton Grossman Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Herbert Barton Grossman's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. (2003) (2206)
Mutations of the VHL tumour suppressor gene in renal carcinoma (1994) (1721)
Epidemiology and risk factors of urothelial bladder cancer. (2013) (1625)
Corrigendum: Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer (2009) (1432)
Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. (2000) (1116)
A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. (1991) (541)
Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. (2005) (421)
Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. (1996) (389)
Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. (2013) (372)
Amplification/overexpression of a mitotic kinase gene in human bladder cancer. (2002) (305)
A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. (2007) (300)
Focus on bladder cancer. (2004) (292)
Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. (2006) (278)
A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. (2007) (277)
Detection of bladder cancer using a point-of-care proteomic assay. (2005) (277)
Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. (2010) (274)
Evaluation of genetic variants in microRNA-related genes and risk of bladder cancer. (2008) (269)
Renal cell carcinoma as an incidental finding. (1985) (267)
Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer (2009) (253)
Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience. (2004) (245)
Clinical model of lifetime cost of treating bladder cancer and associated complications. (2006) (230)
Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. (2006) (217)
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. (2010) (198)
Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer (2015) (195)
Urine markers for detection and surveillance of non-muscle-invasive bladder cancer. (2011) (182)
Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. (2012) (174)
Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. (2005) (172)
Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder. (1998) (163)
Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. (2005) (159)
Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center. (2013) (148)
Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: implications for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer (1999) (140)
Plasma levels of insulin-like growth factor-1 and binding protein-3, and their association with bladder cancer risk. (2003) (126)
A multicenter trial evaluation of the fibrin/fibrinogen degradation products test for detection and monitoring of bladder cancer. (1997) (123)
Fatal sepsis following intravesical bacillus Calmette-Guerin administration for bladder cancer. (1990) (121)
Preliminary assessment of fluorine-18 fluorodeoxyglucose positron mission tomography in patients with bladder cancer (1997) (118)
Outcome analysis of 42 cases of renal angiomyolipoma. (1994) (114)
Germ cell tumor: differentiation of viable tumor, mature teratoma, and necrotic tissue with FDG PET and kinetic modeling. (1999) (111)
Ability of clinical grade to predict final pathologic stage in upper urinary tract transitional cell carcinoma: implications for therapy. (2007) (110)
Liposarcoma of the spermatic cord: report of 6 cases and review of the literature. (1995) (105)
Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder? (2003) (104)
Considerations on implementing diagnostic markers into clinical decision making in bladder cancer. (2010) (101)
Localization of the prostatic apex for radiation therapy using implanted markers. (1993) (98)
Age and body mass index are independent risk factors for the development of postoperative paralytic ileus after radical cystectomy. (2010) (97)
A genome-wide association study of bladder cancer identifies a new susceptibility locus within SLC14A1, a urea transporter gene on chromosome 18q12.3. (2011) (97)
The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies (2015) (96)
Dietary isothiocyanates, GSTM1, GSTT1, NAT2 polymorphisms and bladder cancer risk (2007) (95)
High-Order Interactions among Genetic Variants in DNA Base Excision Repair Pathway Genes and Smoking in Bladder Cancer Susceptibility (2007) (95)
Phase I trial of intravesical recombinant adenovirus mediated interferon-α2b formulated in Syn3 for Bacillus Calmette-Guérin failures in nonmuscle invasive bladder cancer. (2013) (94)
Staging of bladder carcinoma: MRI-CT-surgical correlation. (1986) (94)
Genetic instability in bladder cancer assessed by the comet assay. (2003) (93)
The relationship of local control to distant metastasis in muscle invasive bladder cancer. (1995) (93)
Polymorphisms of folate metabolic genes and susceptibility to bladder cancer: a case-control study. (2004) (92)
Upper urinary tract tumors with nontransitional histology: a single-center experience. (2006) (91)
A stage specific approach to tumor surveillance after radical cystectomy for transitional cell carcinoma of the bladder. (1999) (91)
Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. (2014) (88)
An association between NQO1 genetic polymorphism and risk of bladder cancer. (2003) (86)
Molecular Detection of Noninvasive and Invasive Bladder Tumor Tissues and Exfoliated Cells by Aberrant Promoter Methylation of Laminin-5 Encoding Genes (2004) (84)
125I implantation for carcinoma of prostate. Further follow-up of first 100 cases. (1982) (84)
Malignant melanoma of the penis and male urethra. (1984) (81)
Expression of mal is associated with urothelial differentiation in vitro: identification by differential display reverse-transcriptase polymerase chain reaction. (1997) (80)
Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer (2018) (79)
Reproducibility of p53 Immunohistochemistry in Bladder Tumors (2000) (79)
Matrix metalloproteinase polymorphisms and bladder cancer risk. (2006) (78)
Improved growth of human urothelial carcinoma cell cultures. (1986) (78)
Bladder carcinoma in patients age 40 years or younger (1989) (77)
Role of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand in Interferon-Induced Apoptosis in Human Bladder Cancer Cells (2004) (77)
Imaging of renal cancer using positron emission tomography with 2-deoxy-2-(18F)-fluoro-D-glucose: pilot animal and human studies. (1991) (75)
Modulation of DNA damage/DNA repair capacity by XPC polymorphisms. (2008) (71)
Quantitation of Aurora kinase A gene copy number in urine sediments and bladder cancer detection. (2008) (71)
Aurora-A/STK15/BTAK enhances chromosomal instability in bladder cancer cells. (2004) (71)
Prostate cancer: correlation of MR images with tissue optical density at pathologic examination. (1991) (70)
Sulfotransferase 1A1 (SULT1A1) polymorphism and bladder cancer risk: a case-control study. (2003) (70)
Differential expression of progression-related genes in the evolution of superficial to invasive transitional cell carcinoma of the bladder. (2001) (70)
In vivo gene therapy of human bladder cancer with PTEN suppresses tumor growth, downregulates phosphorylated Akt, and increases sensitivity to doxorubicin (2003) (68)
High-order interactions among genetic polymorphisms in nucleotide excision repair pathway genes and smoking in modulating bladder cancer risk. (2007) (68)
Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: a Southwest Oncology Group Study. (2001) (68)
Projecting individualized probabilities of developing bladder cancer in white individuals. (2007) (68)
Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategy (2008) (67)
Effects of mTOR Inhibitor Everolimus (RAD001) on Bladder Cancer Cells (2009) (65)
Commentary on A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: A retrospective experience (2009) (65)
An improved intravesical model using human bladder cancer cell lines to optimize gene and other therapies (2000) (64)
Screening for bladder cancer: rationale, limitations, whom to target, and perspectives. (2013) (64)
Outcome of patients with bladder cancer with pN+ disease after preoperative chemotherapy and radical cystectomy. (2009) (63)
Mutations Within the Kinase Domain and Truncations of the Epidermal Growth Factor Receptor Are Rare Events in Bladder Cancer: Implications for Therapy (2006) (62)
Relationship among cystectomy, microvessel density and prognosis in stage T1 transitional cell carcinoma of the bladder. (1998) (62)
Expression of the alpha6beta4 integrin provides prognostic information in bladder cancer. (2000) (62)
Phase III Prevention Trial of Fenretinide in Patients with Resected Non–Muscle-Invasive Bladder Cancer (2008) (60)
Significance of upper urinary tract urothelial thickening and filling defect seen on MDCT urography in patients with a history of urothelial neoplasms. (2010) (59)
Selective cyclooxygenase-2 inhibitors inhibit growth and induce apoptosis of bladder cancer. (2006) (56)
Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations. (2016) (56)
Connexin 26 induces growth suppression, apoptosis and increased efficacy of doxorubicin in prostate cancer cells. (2004) (56)
Cytokeratin 20, AN43, PGDH, and COX-2 expression in transitional and squamous cell carcinoma of the bladder. (2003) (55)
Connexin 26 gene therapy of human bladder cancer: induction of growth suppression, apoptosis, and synergy with Cisplatin. (2001) (55)
Glutathione peroxidase 1 gene polymorphism and risk of recurrence in patients with superficial bladder cancer. (2005) (53)
Genetic Variations in the Sonic Hedgehog Pathway Affect Clinical Outcomes in Non–Muscle-Invasive Bladder Cancer (2010) (53)
Chemoprevention of bladder cancer (2008) (53)
Profiling of Genetic Variations in Inflammation Pathway Genes in Relation to Bladder Cancer Predisposition (2008) (51)
Death receptor 4 and bladder cancer risk. (2003) (51)
Carcinoma of the prostate: MR images obtained with body coils do not accurately reflect tumor volume. (1991) (51)
Ureteroscopic treatment of urothelial carcinoma of the ureter and renal pelvis. (1992) (51)
Cytokine-induced gene expression of interleukin-8 in human transitional cell carcinomas and renal cell carcinomas. (1992) (50)
Radical cystectomy for invasive bladder cancer in the octogenarian. (2001) (50)
Clinical model of cost of bladder cancer in the elderly. (2008) (50)
Centrosomal abnormality is common in and a potential biomarker for bladder cancer (2003) (49)
Alterations in transcription clusters underlie development of bladder cancer along papillary and nonpapillary pathways (2005) (48)
Forerunner genes contiguous to RB1 contribute to the development of in situ neoplasia (2007) (47)
A Randomized Controlled Trial of Celecoxib to Prevent Recurrence of Nonmuscle-Invasive Bladder Cancer (2011) (46)
Genotypes, haplotypes and diplotypes of XPC and risk of bladder cancer. (2006) (45)
Polymorphisms in XPD Exons 10 and 23 and Bladder Cancer Risk (2005) (44)
Dietary carotenoids and genetic instability modify bladder cancer risk. (2004) (44)
Urinary nuclear matrix protein 22 (NMP22): A diagnostic adjunct to urine cytologic examination for the detection of recurrent transitional‐cell carcinoma of the bladder (1999) (44)
Characterization of a panel of cell lines derived from urothelial neoplasms: genetic alterations, growth in vivo and the relationship of adenoviral mediated gene transfer to coxsackie adenovirus receptor expression. (2006) (42)
Biomarker study of primary nonmetastatic versus metastatic invasive bladder cancer. National Cancer Institute Bladder Tumor Marker Network. (1998) (42)
Retinoids in the chemoprevention of bladder cancer (1998) (42)
Uptake of 2-deoxy-2-[18F]fluoro-d-glucose in the normal testis: Retrospective PET study and animal experiment (1997) (41)
Bladder tumors in two young males occupationally exposed to MBOCA. (1988) (41)
Matrix Metalloproteinase Polymorphisms Are Associated with Bladder Cancer Invasiveness (2007) (40)
Genetic polymorphism in bladder cancer. (2007) (39)
Connexin 26 is abnormally expressed in bladder cancer. (2003) (39)
Hybridoma antibodies reactive with human bladder carcinoma cell surface antigens. (1983) (39)
Analysis of the expression of biomarkers in urinary bladder cancer using a tissue microarray (2008) (39)
Infarction-nephrectomy for metastatic renal carcinoma. Southwest oncology group study. (1985) (39)
Oral bropirimine immunotherapy of carcinoma in situ of the bladder: results of a phase II trial. (1996) (38)
Considerations on the use of urine markers in the management of patients with low-/intermediate-risk non-muscle invasive bladder cancer. (2014) (37)
Plasma vitamins E and A and risk of bladder cancer: a case–control analysis (2008) (37)
Roles of tumor suppressor and telomere maintenance genes in cancer and aging--an epidemiological study. (2005) (36)
Practical use of perioperative chemotherapy for muscle-invasive bladder cancer: summary of session at the Society of Urologic Oncology annual meeting. (2012) (36)
Matrix metalloproteinase polymorphisms are associated with bladder cancer invasiveness. (2007) (36)
Case-Control Analysis of Dietary Folate and Risk of Bladder Cancer (2005) (35)
Personal Permanent Hair Dye Use Is Not Associated with Bladder Cancer Risk: Evidence from a Case-Control Study (2006) (35)
Urothelial carcinoma occurring within an inverted papilloma of the ureter. (1990) (35)
Variations in reconstruction after radical cystectomy (2007) (34)
Characterization of the DD23 tumor-associated antigen for bladder cancer detection and recurrence monitoring. Marker Network for Bladder Cancer. (1996) (33)
Epidemiology, prevention, screening, diagnosis, and evaluation: update of the ICUD–SIU joint consultation on bladder cancer (2018) (33)
Energy Balance, the PI3K-AKT-mTOR Pathway Genes, and the Risk of Bladder Cancer (2010) (33)
The utility of fibrin/fibrinogen degradation products in superficial bladder cancer. (2000) (33)
Adriamycin versus BCG in superficial bladder cancer: a Southwest Oncology Group Study. (1989) (32)
Malignant mesothelioma of the tunica vaginalis. (2005) (32)
Increased plasma levels of angiogenin and the risk of bladder carcinoma (2005) (32)
Pseudosarcomatous and sarcomatous proliferations of the bladder. (2007) (32)
Identification of effective retinoids for inhibiting growth and inducing apoptosis in bladder cancer cells. (2001) (32)
Reproducibility of p53 immunohistochemistry in bladder tumors. National Cancer Institute, Bladder Tumor Marker Network. (2000) (31)
Urinary tract diseases and bladder cancer risk: a case–control study (2007) (30)
Deoxyribonucleic acid ploidy enhances the cytological prediction of recurrent transitional cell carcinoma of the bladder. (1997) (30)
Premalignant and early carcinomas of the penis and scrotum. (1992) (30)
Mapping and Genome Sequence Analysis of Chromosome 5 Regions Involved in Bladder Cancer Progression (2001) (30)
Bacillus calmette-guérin failures and beyond: contemporary management of non-muscle-invasive bladder cancer. (2008) (30)
PTEN gene therapy induces growth inhibition and increases efficacy of chemotherapy in prostate cancer. (2005) (29)
Screening workers exposed to 4,4'-methylenebis(2-chloroaniline) for bladder cancer by cystoscopy. (1990) (29)
DNA and PCNA content of renal cell carcinoma and prognosis. (1995) (29)
Recent developments in the pathophysiology of bladder cancer. (1994) (28)
Human renal carcinoma: characterization of five new cell lines. (1985) (28)
Comparison of 15 monoclonal antibodies against tumor-associated antigens of transitional cell carcinoma of the human bladder. (1991) (27)
1010 HEXVIX® FLUORESCENCE CYSTOSCOPY IMPROVES DETECTION AND RESECTION OF PAPILLARY BLADDER CANCER AND REDUCES EARLY RECURRENCE: A MULTICENTRE, PROSPECTIVE, RANDOMIZED STUDY (2009) (27)
Combined morphologic and fluorescence in situ hybridization analysis of voided urine samples for the detection and follow-up of bladder cancer in patients with benign urine cytology (2008) (26)
Whole-Organ Genomic Characterization of Mucosal Field Effects Initiating Bladder Carcinogenesis. (2019) (26)
UM-SCP-1, a new human cell line derived from a prostatic squamous cell carcinoma. (1984) (26)
β4 Integrin Transfection of UM-UC-2 (Human Bladder Carcinoma) Cells: Stable Expression of a Spontaneous Cytoplasmic Truncation Mutant with Rapid Loss of Clones Expressing Intact β4 (1997) (25)
Current therapy of bladder carcinoma. (1979) (25)
In vivo and in vitro MR imaging of renal tumors: histopathologic correlation and pulse sequence optimization. (1988) (25)
Microhematuria assessment an IBCN consensus-Based upon a critical review of current guidelines. (2016) (25)
DD23 Biomarker: a prospective clinical assessment in routine urinary cytology specimens from patients being monitored for TCC. (2002) (24)
UM-UC-1 and UM-UC-2: characterization of two new human transitional cell carcinoma lines. (1984) (24)
New methods for detection of bladder cancer. (1998) (24)
Genetic mapping and DNA sequence-based analysis of deleted regions on chromosome 16 involved in progression of bladder cancer from occult preneoplastic conditions to invasive disease (2001) (24)
Intake of red meat and heterocyclic amines, metabolic pathway genes and bladder cancer risk (2012) (24)
Evidence for alternative candidate genes near RB1 involved in clonal expansion of in situ urothelial neoplasia (2006) (23)
Comparative Outcomes of Bladder Cancer (2006) (23)
Expression of survivin, a novel inhibitor of apoptosis, in superficial transitional cell carcinoma of the bladder (2004) (23)
Workshop on imaging science development for cancer prevention and preemption. (2006) (23)
Noninvasive detection of bladder cancer in an orthotopic murine model with green fluorescence protein cytology. (2003) (23)
Chemoprevention of superficial bladder cancer. (2002) (22)
Urinary markers in screening patients with hematuria (2008) (22)
Safety of hexaminolevulinate for blue light cystoscopy in bladder cancer. A combined analysis of the trials used for registration and postmarketing data. (2014) (22)
Bladder Cancer: Chemoprevention, complementary approaches and budgetary considerations (2008) (22)
The pharmacogenetic impact of inflammatory genes on bladder cancer recurrence. (2005) (21)
The 19q12 bladder cancer GWAS signal: association with cyclin E function and aggressive disease. (2014) (21)
Phase 1b Trial to Evaluate Tissue Response to a Second Dose of Intravesical Recombinant Adenoviral Interferon α2b Formulated in Syn3 for Failures of Bacillus Calmette–Guerin (BCG) Therapy in Nonmuscle Invasive Bladder Cancer (2016) (20)
Adverse reactions to the intravesical administration of doxorubicin hydrochloride: report of 6 cases. (1986) (20)
Forced COX-2 expression induces PGE(2) and invasion in immortalized urothelial cells. (2008) (19)
Demonstration of recurrent dedifferentiated liposarcoma of the spermatic cord by FDG-PET (1997) (18)
Transitional cell carcinoma of the bladder: patterns of recurrence after cystectomy as determined by CT. (1991) (18)
Improving the management of bladder cancer with fluorescence cystoscopy. (2007) (17)
Is folic acid safe for non-muscle-invasive bladder cancer patients? An evidence-based cohort study. (2018) (17)
Medical management of renal actinomycosis. (2004) (17)
Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response (2007) (17)
Hormonal therapy of prostatic carcinoma: is there a rationale for delayed treatment? (1986) (17)
Fluorescence cystoscopy: is it ready for use in routine clinical practice? (2006) (17)
Methyl‐CpG‐binding domain 2 (2004) (16)
The use of short tandem repeat profiling to characterize human bladder cancer cell lines. (2009) (16)
Management of patients with Bacilli Calmette-Guérin-refractory carcinoma in situ of the urinary bladder: cost implications of a clinical trial for valrubicin. (2000) (15)
Superficial bladder cancer: decreasing the risk of recurrence. (1996) (15)
Evaluation of Ki67, p53 and angiogenesis in patients enrolled in a randomized study of neoadjuvant chemotherapy with or without cystectomy: a Southwest Oncology Group Study. (2006) (15)
Proteomic assays for the detection of urothelial cancer. (2010) (15)
A genome-wide association study of bladder cancer identifies a new susceptibility locus within SLC 14 A 1 , a urea transporter gene on chromosome 18 q 12 . 3 (2011) (15)
Fibronectin distribution in normal and malignant urothelium. (1990) (14)
Concepts for banking tissue in urologic oncology--the International Bladder Cancer Bank. (2005) (14)
Combined effect of chemopreventive agent N-(4-hydroxyphenyl) retinamide (4-HPR) and gamma-radiation on bladder cancer cell lines. (1998) (14)
Small cell carcinoma of the urinary bladder: a clinicopathologic analysis of 64 patients (2005) (14)
Is radical cystectomy indicated in patients with regional lymphatic metastases? (1988) (13)
Can Biomarkers Guide the Use of Neoadjuvant Chemotherapy in T2 Bladder Cancer? (2019) (13)
Is Exam under Anesthesia Still Necessary for the Staging of Bladder Cancer in the Era of Modern Imaging? (2015) (13)
The use of urine-based biomarkers in bladder cancer. (2006) (13)
Long-term assessment of renal function following nephrectomy for stage I renal carcinoma. (1994) (13)
957 Long-term reduction in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy (2012) (12)
The Prognostic Significance of S–Phase Analysis in Stage Ta/T1 Bladder Cancer (2000) (12)
Cardiac history and risk of post-cystectomy cardiac complications. (2009) (12)
Significance of downstaging in muscle-invasive bladder cancer treated with preoperative radiotherapy. (1997) (11)
Pelvic CT Findings after Radical Prostatectomy (1993) (11)
Treatment of T3a bladder cancer with iridium implantation. (1993) (11)
Bladder contracture following intravesical BCG immunotherapy. (1993) (10)
Cystectomy in the elderly. (2001) (10)
HEXAMINOLEVULINATE FLUORESCENCE CYSTOSCOPY IMPROVES DETECTION AND RESECTION OF PAPILLARY BLADDER CANCER LESIONS AND REDUCES EARLY RECURRENCES (2009) (10)
Markers of bladder cancer State of the art. (2000) (10)
Benzo[a]pyrene diol epoxide‐induced 9p21 aberrations associated with genetic predisposition to bladder cancer (2004) (10)
Cystometry in children. (1977) (10)
Management of rectal injuries during radical cystectomy. (1989) (10)
Detection of Bladder Cancer Using Proteomic Profiling of Urine Sediments (2012) (10)
Radioimmunodetection of a transplantable human bladder carcinoma in a nude mouse. (1984) (10)
264: The Use of Hexvix and Fluorescence Cystoscopy as an Adjunct in the Diagnosis of Carcinoma in Situ of the Urinary Bladder (2004) (10)
Multifocal transitional cell carcinoma of the bladder and upper urinary tract: molecular screening of clonal origin by characterizing CD44 alternative splicing patterns (2005) (9)
Visual disturbances in TUR reaction. (1985) (9)
BCAN Think Tank session 3: Prevention of bladder cancer. (2010) (9)
263: The Use of Hexvix and Fluorescence Cystoscopy as an Adjunct in the Diagnosis of Stage TA/T1 Urothelial Cancer in the Urinary Bladder (2004) (9)
The value of histopathological prognostic factors in superficial bladder cancer: Do we need more? (2000) (9)
Are biomarkers for bladder cancer beneficial? (2010) (9)
FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumors (2008) (9)
Biomarkers for transitional cell carcinoma-pro. (2001) (8)
The late recurrence of grade I transitional cell carcinoma of the ureter after conservative therapy. (1978) (8)
Salvage cystectomy following failed definitive radiation therapy for transitional cell carcinoma of bladder. (1985) (8)
Tumor markers in urology. (1985) (8)
Carcinosarcoma of bladder. Evaluation by electron microscopy and immunohistochemistry. (1984) (7)
Evaluation of a new bladder tumor marker. (1991) (7)
Stomal construction and reconstruction. (1986) (7)
Basal cell carcinoma of scrotum. (1981) (7)
Increased plasma levels of angiogenin and the risk of bladder carcinoma: from initiation ot recurrence. (2005) (7)
Bladder cancer markers in patient management: the current perspective (2008) (7)
MAINTENANCE BCG IMMUNOTHERAPY: EVIDENCE OF ADDITIONAL PROTECTION AGAINST CANCER (1999) (7)
AGE-SPECIFIC REFERENCE RANGES FOR PSA IN THE DETECTION OF PROSTATE CANCER (1997) (7)
Isolated testicular leukemic relapse. Response to radiation therapy. (1987) (6)
Urethral cyst in a man. (1988) (6)
Bladder cancer: neoadjuvant is new again. (2011) (6)
Prognostic significance of DNA ploidy in Ta/Tl bladder cancer: A southwest oncology group study. (1996) (6)
If cystectomy is insufficient, what is an urologist to do? (2003) (6)
Combination cisplatin and dichloromethotrexate in patients with advanced bladder cancer. Phase 2. A Southwest Oncology Group study. (1992) (6)
Southwest Oncology Group Comparison of Bacillus Calmette-Guerin and Doxorubricin in the Treatment and Prophylaxis of Superficial Bladder Cancer (1987) (6)
Acute ureteral obstruction from buckshot. (1980) (6)
913: Results of a Randomized Chemoprevention Trial with Fenretinide in Non-Muscle Invasive Bladder Cancer (2005) (5)
Loss of Co-Localization of a6f34 Integrin and Collagen VII in Bladder Cancer (2007) (5)
Specific chromosome aberrations in peripheral blood lymphocytes are associated with risk of bladder cancer (2004) (5)
Further Follow-up of First 100 Cases (1982) (5)
Energy Balance , the PI 3 K-AKT-mTOR Pathway Genes , and the Risk of Bladder Cancer (2010) (5)
Evaluation of Ki 67 , p 53 and angiogenesis in patients enrolled in a randomized study of neoadjuvant chemotherapy with or without cystectomy : A Southwest Oncology Group study (2006) (5)
Selective COX-2 inhibitors as chemopreventive and therapeutic agents. (2003) (4)
Reproducibility of p 53 Immunohistochemistry in Bladder Tumors 1 (2000) (4)
Biocarbon ureterostomy device for urinary diversion. Multicenter clinical trial. (1989) (4)
Acquired crossed renal ectopia secondary to a giant renal cyst. (1994) (4)
Expression of multidrug resistance gene product (P-glycoprotein) in transitional cell carcinomas of the upper urinary tract. (1994) (4)
Preoperative devascularization of advanced renal adenocarcinoma using a sclerosing agent. (1987) (4)
577 Photodynamic diagnosis of non-muscle invasive bladder cancer with hexaminolevulinate cystoscopy: A meta-analysis (2013) (4)
INITIAL DIAGNOSIS OF BLADDER CANCER USING A POINT-OF-CARE ASSAY (2006) (4)
A New Probe for Bipolar Diathermy for Upper Urothelial Tract Tumors (1987) (4)
Erratum to: The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies (2016) (4)
Autologous antibodies to human bladder cancer (2004) (3)
891: Surveillance of Patients with a History of Bladder Cancer Using a Point-of-Care Proteomic Assay (2006) (3)
Erratum to: The UBC-40 Urothelial Bladder Cancer Cell Line Index: a genomic resource for functional studies (2015) (3)
Innovation in Bladder Cancer Immunotherapy (2016) (3)
Comparison of tissue culture cells and histological sections for use in screening monoclonal antibodies. (1985) (3)
Staging and prognosis of T3b bladder cancer. (1996) (3)
Chemoprevention of bladder cancer. (2006) (3)
Localization of the prostatic apex for radiotherapy using implantable markers (1992) (3)
Expression of the VLA (31 Integrin Family in Bladder Cancer (2007) (3)
Re: Long-term Benefit of 5-Aminolevulinic Acid Fluorescence-Assisted Transurethral Resection of Superficial Bladder Cancer: 5-year Results of a Prospective Randomised Study (2006) (2)
RESULTS OF A PHASE II/III TRIAL OF CELECOXIB TO PREVENT RECURRENCE OF NON-MUSCLE INVASIVE BLADDER CANCER (2009) (2)
Renal cell carcinoma in a patient with mesenteric lipodystrophy. (1995) (2)
Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: A randomised controlled trial (2006) (2)
Complications of 125I implantation: inability to deflate Foley catheter. (1986) (2)
Imaging of a human bladder tumor in nude mice using radiolabeled monoclonal antibody (1984) (2)
Evaluation of N-Acetylneuraminic Acid, Carcinoembryonic Antigen, and Alpha-Fetoprotein as Markers for Advanced Carcinoma (1988) (2)
Localized bladder cancer (2000) (2)
Seminoma associated with crossed fused renal ectopia. (1990) (2)
New treatment approaches for superficial and invasive bladder cancer. (1998) (2)
Commentary on Surgery for metastatic urothelial carcinoma with curative intent: The German experience (AUO AB 30/05) (2009) (2)
Objective treatment response to endocrine therapy in metastatic prostate cancer. (1992) (2)
Can we reliably identify patients for radical cystectomy without neoadjuvant chemotherapy? (2011) (2)
Tissue microarray analysis of pAkt, PTEN and L-plastin in urinary bladder cancer (2005) (2)
Recent developments in the treatment of bladder cancer. (2003) (2)
Tumor suppressor genes of bladder cancer and potential for gene therapy. (2003) (2)
Abstract 2825: Red meat and heterocyclic amine intake, metabolic pathway genes, and bladder cancer risk (2010) (2)
The International Bladder Cancer Network. (2010) (2)
Androgen stimulated chemotherapy in the dunning R-3327 prostatic adenocarcinoma (2004) (2)
Tumor Markers in Genitourinary Cancer (1984) (1)
Words of wisdom. Re: radical cystectomy with extended lymphadenectomy: evaluating separate package versus en bloc submission for node positive bladder cases. (2007) (1)
607: Aurora a as a Potential Biomarker for Bladder Cancer (2005) (1)
Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapy (2004) (1)
Profiling the evolution of human metastatic bladder cancer (2005) (1)
Phase III bladder cancer chemoprevention trial with fenretinide. (2006) (1)
Diagnostic value of routine bone scintigraphy renal imaging in renal cell carcinoma. (1989) (1)
Detection of Bladder Cancer Using a Proteomic Assay—Reply (2005) (1)
Neoadjuvant chemotherapy for bladder cancer. (2003) (1)
Oncology: bladder and testis (1995) (1)
Natural antibody to a human bladder carcinoma cell line (2004) (1)
Comparison of multitarget fluorescence in situ hybridization in urine with other noninvasive tests for detecting bladder cancer (2004) (1)
1668 LONG-TERM CLINICAL BENEFIT OF HEXAMINOLEVULINATE ENABLED FLUORESCENCE CYSTOSCOPY (2012) (1)
Intravesical Therapy – BCG and Beyond (2019) (1)
Fluorescence in situ hybridization for detecting transitional cell carcinoma: Implications for clinical practice: Laudadio J, Keane TE, Reeves HM, Savage SJ, Hoda RS, Lage JM, Wolff DJ, Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, SC (2006) (1)
Gene expression profiling of noninvasive primary urothelial tumours using microarrays (2006) (1)
Phase III PreventionTrial of Fenretinide in Patients with Resected Non ^ Muscle-Invasive Bladder Cancer (2007) (1)
Transitional cell carcinoma of the bladder with involvement of vasa deferentia. (1998) (1)
Is adjuvant chemotherapy for bladder cancer safer in patients with an ileal conduit than a neobladder (2006) (1)
NMP22 and Surveillance for Recurrent Bladder Cancer—Reply (2006) (1)
MP65-03 IS EXAM UNDER ANESTHESIA STILL NECESSARY FOR THE STAGING OF BLADDER CANCER IN THE ERA OF MODERN IMAGING? (2014) (1)
Urothelial neoplasms in patients 20 years or younger: A clinicopathological analysis using the World Health Organization 2004 bladder consensus classification (2006) (1)
POD-07.01: Hexaminolevulinate New Data: Results from the Recurrence Study (2009) (1)
Multigenic and dietary analysis of bladder cancer risk on special reference on nucleotide excision repair and folate intake (2004) (0)
1113: Micropapillary Transitional Cell Carcinoma of the Bladder: A Retrospective Review of the Experience with 100 Consecutive Patients (2005) (0)
The Use of Tumor Markers in Bladder Cancer and Current Concepts on Clinical Applicability (2001) (0)
WP744, an novel anthracycline highly active against wild-type and doxorubicin-resistant bladder cancer cell lines (2005) (0)
Commentary on “Paclitaxel gelatin nanoparticles for intravesical bladder cancer therapy.” Lu Z, Yeh TK, Wang J, Chen L, Lyness G, Xin Y, Wientjes MG, Bergdall V, Couto G, Alvarez-Berger F, Kosarek CE, Au JL, Optimum Therapeutics, L.L.C., Columbus, OH (2012) (0)
Is Heparin Contraindicated in Pelvic Lymphadenectomy and Radical Prostatectomy?: Editorial Comment (1997) (0)
618: Identification of Apoptosis and Cell Cycle Related Genes Induced by Connexin-26 Expression in Human Bladder Cancer Cell Lines (2006) (0)
777: Tissue Microarray Analysis of pAkt, PTEN and L-Plastin in Urinary Bladder Cancer (2005) (0)
Commentary on Laparoscopic radical cystectomy for muscle-invasive bladder cancer: pathological and oncological outcomes (2009) (0)
Re: Reduced Bladder Cancer Recurrence Rate with Cardioprotective Aspirin After Intravesical Bacille Calmette-Guérin (2010) (0)
Function and Aggressive Disease The 19 q 12 Bladder Cancer GWAS Signal : Association with Cyclin E Updated (2014) (0)
The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study (2007) (0)
The effect of single dose N-methyl-N-nitrosourea on bladder carcinogenesis by N-[4-(5-nitro-2-furyl)-2-thiazolyl] formamide in rats. (1981) (0)
Editorial Comment: p53 Mutations and Prognosis in Bladder Tumors (1995) (0)
Abstract 5066: Genome sequence and epigenome map of bladder cancer development from occult field effects (2012) (0)
Abstract 894: Genetic variations in the angiogenesis pathway modulate clinical outcomes of bladder cancer (2010) (0)
Low incidence of perioperative chemotherapy for Stage III bladder cancer 1998 to 2003: A report from the National Cancer Data Base (2008) (0)
433: Malignant Mesotheliomas of the Tunica Vaginalis: Review of the University of Texas M.D. Anderson Cancer Center Experience (2005) (0)
Death Receptor 4 and Bladder Cancer Risk 1 (2003) (0)
Commentary on “Trends in hospital volume and operative mortality for high-risk surgery.” Finks JF, Osborne NH, Birkmeyer JD, Center for Healthcare Outcomes and Policy and the Section of General Surgery, Department of Surgery, University of Michigan, Ann Arbor, MI (2012) (0)
Abstract 3065: Loss of ARL11 function promotes growth ofin situneoplasia by activating the ras pathway (2010) (0)
The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies (2015) (0)
771: Polymorphisms in Inflammation Genes and Bladder Cancer: From Initiation to Recurrence, Progression, and Survival (2005) (0)
Commentary on Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer (2009) (0)
606: Identification of AN43, a Tumor Associated Antigen Found in Bladder Cancer (2005) (0)
ASSOCIATION OF EGFR FAMILY POLYMORPHISMS AND BLADDER CANCER RISK (2008) (0)
Diagnosis and treatment of bladder carcinoma. (1986) (0)
Commentary (Grossman): Age-Specific Reference Ranges for PSA in the Detection of Prostate Cancer (1997) (0)
Autologous Reactivity of Bladder Cancer Patients (1987) (0)
Intravesical therapy in superficial bladder cancer. Commentary (1994) (0)
856: Dietary Carotenoids and Genetic Instability Modify Bladder Cancer Risk (2005) (0)
Prognostic value of p53 and MIB-1 in transitional cell carcinoma of the urinary bladder with regional lymph node involvement (2005) (0)
1293 A META-ANALYSIS OF BLUE LIGHT CYSTOSCOPY WITH HEXAMINOLEVULINATE IN PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER (2013) (0)
Preoperative plasma soluble E-cadherin predicts metastases to lymph nodes and prognosis in patients undergoing radical cystectomy (2004) (0)
Cancer Therapy : Preclinical Effects of mTOR Inhibitor Everolimus ( RAD 001 ) on Bladder Cancer Cells (2011) (0)
Clinical utility of fluorescent in situ hybridization for the surveillance of bladder cancer patients treated with bacillus Calmette-Guérin therapy (2008) (0)
Abstract B114: Energy balance, the PI3K‐AKT‐mTOR pathway genes and the risk of bladder cancer (2010) (0)
POD-7.13: Robotic-Assisted Laparoscopic Surgery for Invasive Bladder Cancer: Can the Lymph Node Dissection Match the Benchmarks of Open Surgery? (2008) (0)
Long-term outcome of hematuria home screening for bladder cancer in men (2007) (0)
Erratum to: The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies (2016) (0)
1139 Effect of preoperative radiotherapy on clinical-to-pathologic downstaging in muscle-invasive bladder cancer (1995) (0)
Immunotherapy for bladder cancer. Is the black box becoming grayer? (2003) (0)
Editorial comment. (2009) (0)
Natural history of positive urinary cytology after radical cystectomy (2007) (0)
Molecular analysis of a new tumor-specific gene in breast and bladder carcinoma (1993) (0)
Chemotherapy and cystectomy for muscle invasive bladder cancer (2003) (0)
HORMONAL THERAPY OF PROSTATIC CARCIK : ( J ? , ! 4 : IS THERE A RATIONALE FOR DELAYED TREAT (2003) (0)
Expression of multidrug resistance proteins P-glycoprotein, multidrug resistance protein 1, breast cancer resistance protein and lung resistance related protein in locally advanced bladder cancer treated with neoadjuvant chemotherapy: biological and clinical implications (2004) (0)
Prediction of progression in pTa and pT1 bladder carcinomas with p53, p16 and pRb (2005) (0)
Abstract PR-09: Genetic variations in the sonic hedgehog pathway and clinical outcomes in bladder cancer (2010) (0)
The Significance of Immune Cytological Diagnostics for Bladder Carcinoma (1991) (0)
Abstract 5256: Mechanism of field cancerization (2014) (0)
Editorial Comment. (2017) (0)
Tissue microarray analysis of connexin-26 and Drg-1 in urinary bladder cancer (2006) (0)
Presentation, location, and overall survival of pelvic recurrence after radical cystectomy for transitional cell carcinoma of the bladder (2008) (0)
976: Overexpression of Aurora A / STK15/ BTAK Induces Chromosomal Missegregation and Aneuploidy in Urothelial Cells (2004) (0)
Summary of 125I implantation for carcinoma of prostate: further follow-up of first 100 cases (by H.B. Grossman, MD, M. Batata, MD, B. Hilaris, MD, and W.F. Whitmore, Jr, MD). 1982. (1997) (0)
TheUBC-40UrothelialBladderCancercellline index:agenomicresourceforfunctionalstudies (2015) (0)
Treatment of superficial bladder cancer. (1995) (0)
983: Bladder Cancer Predisposition: A Pathway-Based Approach to DNA Repair and Cell Cycle Control Genes (2006) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Herbert Barton Grossman?

Herbert Barton Grossman is affiliated with the following schools: